Ecchymosis on Tegretol is generally a reflection of the adverse reaction of subcutaneous bleeding caused by Tegretol, it is recommended to go to the hospital as soon as possible to follow up, according to the condition of the decision on whether to stop the drug.
Tegretol is a new type of antiplatelet drug, is a non-precursor drug, does not need to be metabolized by the liver, can be fast-acting after oral intake, stable efficacy, can be reversible binding platelet P2Y12 receptor antagonist, after stopping the drug can be quickly restored to the platelet function, can avoid individual differences in the use of medication due to the different polymorphisms of individual hepatic enzyme genes.
Tegretol is now widely used for antiplatelet therapy in patients with acute coronary syndrome (ACS).
Because Tegretol causes an increased risk of bleeding, it should be used with caution in patients with a previous history of gastrointestinal bleeding or a recent history of surgery or trauma with a tendency to bleed; it is contraindicated in patients with a previous history of intracranial hemorrhage, active hemorrhage, moderate-to-severe hepatic injury, and those who are allergic to Tegretol or any of its excipients. Common adverse reactions to this drug include gastrointestinal bleeding, subcutaneous bleeding, dizziness, headache, and diarrhea.
Taking Tegretol is recommended under the supervision of a doctor to avoid unauthorized use or changes in dosage.